Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP
Study Identifier:
D8590C00003
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
Recruiting
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: ALXN1850
- Drug: Placebo
Date
May 2024 - Dec 2025
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 2 - 11 Years
Requirements Information
Sex
Female & Male
Age
2 - 11 Years
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: ALXN1850
- Drug: Placebo
Date
May 2024 - Dec 2025
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 2 - 11 Years years
Requirements Information
Protocol Summary
The primary purpose of this study is to evaluate the efficacy of ALXN1850 versus placebo on radiographic outcomes in pediatric participants with HPP who have not previously been treated with asfotase alfa.
Trial Locations
Location
Status
Location
Research Site
Baltimore, Maryland, United States, 21287
Status
Not yet recruiting
Location
Research Site
Kansas City, Missouri, United States, 64108
Status
Recruiting
Location
Research Site
Durham, North Carolina, United States, 27705
Status
Recruiting
Location
Research Site
Buenos Aires, Argentina, C1199
Status
Recruiting
Location
Research Site
Buenos Aires, Argentina, C1425BPE
Status
Recruiting
Location
Research Site
Mar del Plata, Argentina, B7600FYK
Status
Withdrawn